Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Bought by Paulson & CO. Inc.

Paulson & CO. Inc. grew its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 19.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 554,600 shares of the biopharmaceutical company’s stock after buying an additional 91,600 shares during the quarter. Paulson & CO. Inc. owned approximately 1.01% of Dynavax Technologies Corporation worth $5,352,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. GMT Capital Corp increased its position in Dynavax Technologies Corporation by 28.2% in the second quarter. GMT Capital Corp now owns 3,005,137 shares of the biopharmaceutical company’s stock worth $29,450,000 after buying an additional 660,637 shares in the last quarter. Vanguard Group Inc. increased its position in Dynavax Technologies Corporation by 10.9% in the second quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock worth $19,538,000 after buying an additional 199,004 shares in the last quarter. PointState Capital LP purchased a new stake in Dynavax Technologies Corporation in the second quarter worth about $13,510,000. Kornitzer Capital Management Inc. KS increased its position in Dynavax Technologies Corporation by 4.0% in the second quarter. Kornitzer Capital Management Inc. KS now owns 1,142,360 shares of the biopharmaceutical company’s stock worth $11,024,000 after buying an additional 43,850 shares in the last quarter. Finally, State Street Corp increased its position in Dynavax Technologies Corporation by 19.7% in the second quarter. State Street Corp now owns 839,218 shares of the biopharmaceutical company’s stock worth $8,099,000 after buying an additional 138,112 shares in the last quarter. Institutional investors and hedge funds own 59.83% of the company’s stock.

DVAX has been the subject of a number of analyst reports. Royal Bank Of Canada restated a “buy” rating and issued a $26.00 price target on shares of Dynavax Technologies Corporation in a research report on Friday, September 1st. Cowen and Company restated an “outperform” rating and issued a $45.00 price target on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. William Blair restated an “outperform” rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Cantor Fitzgerald initiated coverage on Dynavax Technologies Corporation in a research report on Friday, September 15th. They issued an “overweight” rating and a $24.00 price target for the company. Finally, ValuEngine upgraded Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $25.00.

ILLEGAL ACTIVITY NOTICE: “Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Bought by Paulson & CO. Inc.” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/27/paulson-co-inc-boosts-position-in-dynavax-technologies-corporation-dvax.html.

Dynavax Technologies Corporation (NASDAQ:DVAX) traded up 3.95% during trading on Friday, hitting $21.05. The stock had a trading volume of 436,807 shares. The company’s market cap is $1.15 billion. Dynavax Technologies Corporation has a 52-week low of $3.20 and a 52-week high of $24.45. The firm’s 50-day moving average price is $21.32 and its 200-day moving average price is $12.73.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.15 million. During the same quarter in the previous year, the business earned ($0.75) EPS. Analysts predict that Dynavax Technologies Corporation will post ($1.63) EPS for the current fiscal year.

Dynavax Technologies Corporation Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply